Announcements Trials

Browse Landscape

Phase

Phase 2 3 Phase 1/2 1

Status

Not yet recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 4 Other hematologic neoplasm 2 Lymphoid 2 Tumor-Agnostic 1 Thoracic 1 Genitourinary 1 Dermatologic 1

Conditions

Lung Neoplasms 1 Carcinoma, Non-Small-Cell Lung 1

Interventions

pembrolizumab 120 Carboplatin 114 Pemetrexed 74 Cisplatin 71 Nivolumab 68 Paclitaxel 58 Docetaxel 56 Radiotherapy 41 Erlotinib Hydrochloride 41 Gemcitabine 35 Etoposide 34 atezolizumab 30 osimertinib 29 Cetuximab 27 Ipilimumab 25 Bevacizumab 25 Radiosurgery 22 durvalumab 21 Cyclophosphamide 20 Drug Therapy 18 130-nm albumin-bound paclitaxel 17 avelumab 14 Taxes 14 Gefitinib 14 Albumin-Bound Paclitaxel 14 Irinotecan 13 Injections 13 fludarabine 11 Radiation 11 cemiplimab 10

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1/2 × capivasertib × Thoracic × Clear all

NCT07486648 2026-03-24

Precision

Shanxi Province Cancer Hospital

Phase 1/2 Not yet recruiting

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡